Commercial Sanofi posts upbeat sales as R&D pressure builds BioPharma DiveA string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over.CommercialRead full story pharminent April 23, 2026 (Last updated: April 23, 2026) BioPharma Dive A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. CommercialRead full story Post navigation Previous: BBOT shakes up leadership as RAS competitors get more visibilityNext: Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs Related Stories Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market pharminent May 8, 2026 Commercial Novo hikes guidance on Wegovy pill’s fast sales start pharminent May 6, 2026 Commercial Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales pharminent May 6, 2026
